BAO PHARMA-B (02659) jumped more than 15% in early trading. As of press time, the stock was up 8.10% at HK$12.55, with a turnover of HK$7.3847 million.

On the news front, clinical research and commercialization of the company's core products are being progressively advanced. The marketing application for KJ103 for desensitization treatment before kidney transplantation in China was submitted in May 2026 and accepted by the drug regulatory authority; the Phase 3 clinical study for desensitization treatment in highly sensitized kidney transplant patients reached its primary endpoint in March 2026, with rapid desensitization effects, a high success rate, and good safety; data from the Phase 2 clinical study for anti-GBM disease were presented at the European Renal Association Congress in June 2026, initially demonstrating clinical value.

KJ017 was approved for marketing in China in March 2026 for assisting subcutaneous infusion, and two Phase 3 clinical study data sets were published in the European Journal of Pharmaceutics and Biopharmaceutics; the company continues to expand cooperation, and as of its 2026 interim report, more than 60 partners had used KJ017 for product development, with projects covering various stages from early research to clinical development.